This is a proof-to-compound story, not a moonshot. The business already has real demand and a live carrier stack, so the key question is whether better
underwriting, lower claims friction, and more bundling can keep improving economics as auto, pet, and partner distribution scale. If that proof arrives, investors can value it less like an experiment and more like a differentiated personal-lines compounder; if not, growth can continue while the multiple stays ordinary.